Now that all the Biogen Idec
On Monday, Biogen outlined its goals and forecasts at the JPMorgan Healthcare Conference in San Francisco. Doing so seems to be a trend in the drug development industry, after Merck
Much of Biogen's forecast for this time frame depends on its and Elan's
In 2008, Biogen expects non-GAAP EPS to range between $3.20 and $3.35, and its 2007 non-GAAP EPS to come in above its previous $2.70 forecast. If Biogen can hit the top of its 2008 financial guidance and experience 15% EPS growth in 2009 and 2010, this will give it $4.43 annualized non-GAAP EPS by the end of 2010.
This isn't bad, considering Biogen's much-reduced share price valuation, but whether Biogen can hit this EPS number will be based on the success of Tysabri and its potential competitors, including Genzyme's
More MS Foolishness: